This paper focuses on pharmacovigilance (PV) and risk management for biosimilars, the issues and challenges faced in monitoring their safety and possible solutions.

In this installment of his column in Bioanalysis Zone, Robert MacNeill explores hydrophilic-interaction liquid chromatography (HILIC) and how the technique is often overlooked.

This white paper discusses current challenges of traditional clinical trials, the emergence of eClinical applications and microservices that can enable virtual trials, barriers to adoption of innovative study delivery models and the role of contract research organizations (CROs) in partnering with biopharma to unlock the benefits of virtual trials and maxi

A large pharmaceutical company wanted to employ central monitoring for their entire inhouse portfolio of approximately 50 studies. Study startup and management was retained by the sponsor and another CRO was assigned to perform on-site monitoring.

SETAC Europe 2020 -- Nanomaterials are an area of increasing scrutiny in a regulatory environment, with regulatory frameworks in development for multiple countries such as the EU, US and Canada. Recently, a specific revision of the REACH information requirements for nanomaterials has been adopted by the European Commission.

SETAC Europe 2020 -- Algae are internationally established test organisms in chemical risk assessment. Toxicity test guidelines incorporating algae are largely focused on traditional apical endpoints such as growth rates following a 72-hr chemical exposure as per OECD 201 guidelines.

LabCorp�, a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, is expanding its technology ecosystem to accelerate the adoption of decentralized clinical trials, often referred to as hybrid and virtual clinical trials.Covance is expanding its decentralized tri

Covance, the drug development business division of LabCorp, announced it was working to expand its technology offerings with solutions intended to speed the industry adoption of decentralized and hybrid trials.

Medable and LabCorp CRO Covance signed a deal to accelerate adoption of decentralized trials, a trend that has been helped along as COVID-19 has created challenges to conducting trials dependent on traditional brick-and-mortar sites.LabCorp, the lab-testing giant, said May 28 that its CRO, Covance, would partner with Medable, a company that makes software